The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setback For Merck’s HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours:
Gilead Recalls Two Lots Of Remdesivir Due To Presence Of Glass Particulates
Gilead Sciences Inc (NASDAQ: GILD) has
December SPAC Merger Calendar: Upcoming Votes, Stocks To Watch
The month of December shows an increasing number of SPAC deal votes.
SPAC merger votes can act as a catalyst, as the votes complete the last step in the merger process and change the company over to a new name and ticker that can help build recognition.
Watching COVID-19 Antibody Drug Stocks; Wall Street Journal Earlier Reports ‘Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates’
https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=hp_lead_pos3
Gilead, AWS Collaborate On Development And Delivery Of New Medicines For Patients
Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ:AMZN), announced that Gilead Sciences, Inc.
Gilead Says Co’s Bold Ambition Of Transforming Triple-Negative Breast Cancer Treatment To Be Highlighted With New Data At SABCS
Gilead Sciences, Inc. (NASDAQ:GILD) will present additional data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) during the upcoming San Antonio Breast Cancer Symposium (SABCS) being held
Why Are NRx Pharma’s Shares Soaring Premarket?
NRx Pharmaceuticals (NASDAQ: NRXP) has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Inc's (NASDAQ: GILD) remdesivir in the COVID
Gilead’s Trodelvy Approved In Europe For Aggressive Form Of Breast Cancer
The European Commission has approved Gilead Sciences Inc's (NASDAQ: